Immunome (IMNM) director offsets 10,500-share buy and sale in Form 4
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Immunome Inc. director Jean Jacques Bienaimé reported offsetting trades in the company’s common stock on June 5, 2026. He made open-market purchases totaling 10,500 shares at prices between $19.27 and $19.48 per share and open-market sales totaling 10,500 shares at prices around $19.41–$19.44 per share, resulting in no net change in shares.
Following these transactions, he directly owned 42,915 shares of Immunome common stock. A footnote states that the sales were matchable with a 1,000‑share purchase under Section 16(b), and he agreed to pay $155 to Immunome, representing the full profit from that short-swing transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
BIENAIME JEAN JACQUES
Role
null
Bought
10,500 shs ($204K)
Sold
10,500 shs ($204K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 500 | $19.44 | $10K |
| Sale | Common Stock | 10,000 | $19.41 | $194K |
| Purchase | Common Stock | 6,000 | $19.48 | $117K |
| Purchase | Common Stock | 3,500 | $19.46 | $68K |
| Purchase | Common Stock | 1,000 | $19.27 | $19K |
Holdings After Transaction:
Common Stock — 42,915 shares (Direct, null)
Footnotes (1)
- The sales by the reporting person reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person at the price of $19.27 per share on June 5, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $155, representing the full amount of the profit realized in connection with the short-swing transaction. The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026.
Key Figures
Shares purchased: 10,500 shares
Purchase prices: $19.27–$19.48 per share
Shares sold: 10,500 shares
+3 more
6 metrics
Shares purchased
10,500 shares
Open-market purchases of Immunome common stock on June 5, 2026
Purchase prices
$19.27–$19.48 per share
Prices for three purchase transactions on June 5, 2026
Shares sold
10,500 shares
Open-market sales of Immunome common stock on June 5, 2026
Sale prices
$19.41–$19.44 per share
Prices for two sale transactions on June 5, 2026
Shares owned after trades
42,915 shares
Director’s direct Immunome holdings following June 5, 2026 transactions
Short-swing profit repaid
$155
Amount the director agreed to pay Immunome under Section 16(b)
Key Terms
open-market purchase, open-market sale, Section 16(b), short-swing transaction
4 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Section 16(b) regulatory
"matchable under Section 16(b) of the Securities Exchange Act of 1934"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
short-swing transaction regulatory
"profit realized in connection with the short-swing transaction"
FAQ
What did Immunome (IMNM) director Jean Jacques Bienaimé report in this Form 4?
He reported both buying and selling Immunome common stock on June 5, 2026. The transactions involved 10,500 shares purchased and 10,500 shares sold, leaving his overall share count unchanged but updating his reported holdings and pricing details.
What are Jean Jacques Bienaimé’s Immunome (IMNM) holdings after these transactions?
After the reported trades, he directly holds 42,915 shares of Immunome common stock. This figure reflects his position following the June 5, 2026 open-market purchases and sales disclosed in the Form 4 insider trading report.
Do these Immunome (IMNM) trades change the director’s net ownership position?
No. The director bought and sold the same aggregate number of 10,500 shares on June 5, 2026. Because purchases and sales were equal, his net ownership level remained unchanged, though his total direct holdings are now reported as 42,915 shares.